Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aspen Pharmacare (APNHY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aspen Pharmacare is a member of our Medical group, which includes 916 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that APNHY has returned about 42.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.9% on average. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Corcept Therapeutics (CORT). The stock has returned 234% year-to-date.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, which includes 12 individual stocks and currently sits at #43 in the Zacks Industry Rank. This group has gained an average of 7.9% so far this year, so APNHY is performing better in this area.
On the other hand, Corcept Therapeutics belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #157. The industry has moved -7.5% year to date.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aspen Pharmacare (APNHY): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).